Rigel Pharmaceuticals logo

Rigel PharmaceuticalsNASDAQ: RIGL

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

29 November 2000

Next earnings report:

05 March 2025

Last dividends:

N/A

Next dividends:

N/A
$401.45 M
-32%vs. 3y high
62%vs. sector
-15%vs. 3y high
92%vs. sector
-27.43
-133%vs. 3y high
2%vs. sector
-60%vs. 3y high
45%vs. sector

Price

after hours | Sat, 16 Nov 2024 00:52:36 GMT
$22.79-$4.22(-15.62%)

Dividend

No data over the past 3 years
$55.31 M$47.42 M
$55.31 M$12.42 M

Analysts recommendations

Institutional Ownership

RIGL Latest News

Rigel Pharmaceuticals (RIGL) Q3 Earnings and Revenues Top Estimates
zacks.com07 November 2024 Sentiment: POSITIVE

Rigel Pharmaceuticals (RIGL) came out with quarterly earnings of $0.70 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to loss of $0.30 per share a year ago.

Rigel Announces Six Poster Presentations at the 66th American Society of Hematology Annual Meeting and Exposition
prnewswire.com05 November 2024 Sentiment: POSITIVE

-    Initial data from the ongoing Phase 1b study evaluating R289, a dual IRAK1/4 inhibitor, in LR-MDS -    Additional data for  REZLIDHIA® (olutasidenib) in patients with mIDH1 AML and MDS SOUTH SAN FRANCISCO, Calif. , Nov. 5, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced upcoming presentations of six posters highlighting data from their commercial and clinical-stage hematology-oncology portfolio at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 7-10, 2024, in San Diego, California and virtually.

Rigel Announces Conference Call and Webcast to Report Third Quarter 2024 Financial Results and Business Update
prnewswire.com31 October 2024 Sentiment: POSITIVE

SOUTH SAN FRANCISCO, Calif. , Oct. 31, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its third quarter 2024 financial results after market close on Thursday, November 7, 2024.

Rigel Pharmaceuticals Issues Dear Healthcare Provider Letter for GAVRETO® (pralsetinib)
prnewswire.com24 October 2024 Sentiment: NEUTRAL

SOUTH SAN FRANCISCO, Calif. , Oct. 24, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced it is issuing a Dear Health Care Provider (DHCP) letter related to a new safety signal for GAVRETO® (pralsetinib) after consultation with the U.S. Food and Drug Administration (FDA).

Rigel Pharmaceuticals: Looking For More Growth
seekingalpha.com10 October 2024 Sentiment: POSITIVE

Rigel Pharmaceuticals' strategic acquisitions of GAVRETO and REZLIDHIA, along with strong TAVALISSE sales, position the company for significant growth and potential profitability. Despite historical negative EPS, Rigel has shown upward revenue trends, with recent earnings revealing a 37.03% year-over-year revenue increase and a reduced net loss. Growth opportunities include expanding product labels, advancing the R289 program, and leveraging partnerships, particularly in the growing hematology and oncology markets.

Rigel Pharma Remains Bullish, Growth Fueled By FDA-Approved Drugs, Strategic Partnerships
seekingalpha.com09 October 2024 Sentiment: POSITIVE

Rigel Pharmaceuticals has surged 50.1% since my previous article, driven by successful execution, innovative portfolio, strategic partnerships, and pipeline progress. RIGL's FDA-approved drugs, Tavalisse, Rezlidhia, and Gavreto, are key revenue drivers. They have experienced significant sales growth and promise future contributions, particularly from Gavreto. The company's international collaborations and ongoing clinical trials, especially for olutasidenib, indicate potential for new revenue streams and competitive IP in hematology and oncology.

Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
prnewswire.com04 October 2024 Sentiment: POSITIVE

SOUTH SAN FRANCISCO, Calif. , Oct. 4, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to Rigel's Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees' entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4).

Rigel (RIGL) Surges 19.7%: Is This an Indication of Further Gains?
zacks.com25 September 2024 Sentiment: POSITIVE

Rigel (RIGL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Rigel Announces First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA® (olutasidenib) in mIDH1 AML
prnewswire.com05 September 2024 Sentiment: POSITIVE

First trial in Rigel's multi-year strategic development alliance with MD Anderson Phase 1b/2 trial of decitabine and venetoclax in combination with Rigel's targeted mIDH1 inhibitor REZLIDHIA for patients with mIDH1 AML SOUTH SAN FRANCISCO, Calif. , Sept. 5, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the first patient has been enrolled in a Phase 1b/2 triplet therapy trial of decitabine and venetoclax in combination with REZLIDHIA® (olutasidenib) in patients with mutated isocitrate dehydrogenase-1 (mIDH1) acute myeloid leukemia (AML).

Rigel Expands Relationship with Kissei to include REZLIDHIA® (olutasidenib) in Japan, the Republic of Korea and Taiwan
prnewswire.com03 September 2024 Sentiment: POSITIVE

Kissei gains exclusive rights to develop and commercialize olutasidenib in all current and potential indications in Japan, the Republic of Korea  and Taiwan Rigel will receive an upfront cash payment of $10.0 million with the potential for up to $152.5 million in future development, regulatory, and commercial milestone payments Rigel to receive product transfer price payments in the mid-twenty to lower-thirty percent range based on tiered net sales for exclusive supply of REZLIDHIA SOUTH SAN FRANCISCO, Calif. , Sept. 3, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced it has entered into an exclusive license and supply agreement with Kissei Pharmaceutical Co., Ltd.

  • 1(current)
  • 2

What type of business is Rigel Pharmaceuticals?

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

What sector is Rigel Pharmaceuticals in?

Rigel Pharmaceuticals is in the Healthcare sector

What industry is Rigel Pharmaceuticals in?

Rigel Pharmaceuticals is in the Biotechnology industry

What country is Rigel Pharmaceuticals from?

Rigel Pharmaceuticals is headquartered in United States

When did Rigel Pharmaceuticals go public?

Rigel Pharmaceuticals initial public offering (IPO) was on 29 November 2000

What is Rigel Pharmaceuticals website?

https://www.rigel.com

Is Rigel Pharmaceuticals in the S&P 500?

No, Rigel Pharmaceuticals is not included in the S&P 500 index

Is Rigel Pharmaceuticals in the NASDAQ 100?

No, Rigel Pharmaceuticals is not included in the NASDAQ 100 index

Is Rigel Pharmaceuticals in the Dow Jones?

No, Rigel Pharmaceuticals is not included in the Dow Jones index

When was Rigel Pharmaceuticals the previous earnings report?

No data

When does Rigel Pharmaceuticals earnings report?

The next expected earnings date for Rigel Pharmaceuticals is 05 March 2025